INBX
Inhibrx Biosciences Inc. · NASDAQ
- Market cap
- $1.23B
Inhibrx Biosciences Inc. (INBX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for INBX, including 3 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 13, 2026.
INBX rankings
Financial highlights
Full financials- Revenue, TTM
- $2.00M
- Revenue growth
- +42.9%
- Net income, TTM
- -$141.66M
- Net margin
- -7082.9%
- Free cash flow, TTM
- -$132.70M
- Cash
- $199.47M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks44+50%
2026-05-242026-11-15
Mix3090d
- Insider13(43%)
- SEC Filings10(33%)
- Other3(10%)
- Earnings2(7%)
- Analyst1(3%)
- 13D/G1(3%)
Activity · 52 weeks6737 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form S-3ASR filed by Inhibrx Biosciences Inc.S-3ASR - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form 10-Q filed by Inhibrx Biosciences Inc.10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports Third Quarter 2026 Financial ResultsSAN DIEGO, Nov. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Upcoming Clinical MilestonesOzekibart (INBRX-109) in Ewing sarcoma. The Company plans to present updated results from the Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with irinotecan and temozolomide in refractory Ewing sarcoma at the annual Connective Tissue Oncology Society (CTOS) meeting in Seoul, South Korea from November 19th-20th, 2026.Ozekibart (INBRX-109) in Ch
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- INSIDERChief Executive Officer Lappe Mark bought $17,152 worth of shares (200 units at $85.76) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- PRInhibrx Announces Participation in Upcoming Scientific ConferencesSAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:2026 European Society for Medical Oncology (ESMO) CongressOctober 25th, 2026 – Madrid, SpainTitle: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysisFormat: Oral Presen
- INSIDERChief Executive Officer Lappe Mark bought $998,784 worth of shares (10,000 units at $99.88) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- INSIDERDirector Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Forsyth Douglas4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Vuori Kristiina Md4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Manhard Kimberly4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Kayyem Jon Faiz4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Manhard Kimberly sold $163,542 worth of shares (1,500 units at $109.03) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- INSIDERDirector Manhard Kimberly sold $115,468 worth of shares (1,000 units at $115.47) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- INSIDERDirector Kayyem Jon Faiz bought $567,580 worth of shares (5,000 units at $113.52) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Forsyth Douglas bought $286,617 worth of shares (2,500 units at $114.65) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
INBX FAQ
10 questionsWhat does Inhibrx Biosciences Inc. do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein...What is the latest news on INBX?
In the last 30 days Quantisnow tracked 6 wire items for INBX: 3 SEC filings, 1 press release or news item, 1 earnings update and 1 13D/G filing. The most recent was published on November 13, 2026.What is INBX revenue?
Inhibrx Biosciences Inc. (INBX) reported $2.00M of revenue for the twelve months ended Sep 30, 2026. That is up 42.9% from the year before. Revenue for fiscal 2025 was $1.30M.Is INBX profitable?
No. Inhibrx Biosciences Inc. reported a net loss of $141.66M for the twelve months ended Sep 30, 2026.How much cash and debt does INBX have?
Inhibrx Biosciences Inc. reported $199.47M in cash and cash equivalents and $276.70M of debt on its most recent balance sheet in SEC filings.Where does INBX stock trade?
Inhibrx Biosciences Inc. (INBX) is listed on NASDAQ.What sector and industry is INBX in?
Inhibrx Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about INBX?
Across the last 8 analyst actions on Inhibrx Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from H.C. Wainwright: Buy with a $245.00 price target on 2026-08-24.What companies are similar to INBX?
Notable peers in the same industry include RVMD (Revolution Medicines Inc.), MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), GILD (Gilead Sciences Inc.). Compare INBX side-by-side with any of them on Quantisnow.How can I track INBX on Quantisnow?
Quantisnow aggregates Inhibrx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBX to receive live email and push alerts on every new disclosure.